Pola-ZR2P in Previously Untreated DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
Trial Details
- NCT ID
- NCT06664411
- Phase
- PHASE2
- Sponsor
- Navy General Hospital, Beijing
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
- Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;
- Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
- Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →